Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
FAQ
- What is Travere Therapeutics, Inc.'s D&A?
- Travere Therapeutics, Inc. (TVTX) reported D&A of $25.21M in Q1 2026.
- How has Travere Therapeutics, Inc.'s D&A changed year-over-year?
- Travere Therapeutics, Inc.'s D&A increased by 96.9% year-over-year, from $12.8M to $25.21M.
- What is the long-term trend for Travere Therapeutics, Inc.'s D&A?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s D&A has grown at a 41.3% compound annual growth rate (CAGR), from $21.51M to $60.74M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Travere Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude